UB Paderborn / Katalog / Suche / in CDI

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA

Cancer, 2018-05, Vol.124 (10), p.2115-2124

2018

Volltextzugriff (PDF)

Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study

European urology oncology, 2020-10, Vol.3 (5), p.695-699

2020

Volltextzugriff (PDF)

Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial

BMC cancer, 2024-04, Vol.24 (1), p.493-493, Article 493

2024

Volltextzugriff (PDF)

Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions

BJU international, 2020-05, Vol.125 (5), p.739-746

2020

Volltextzugriff (PDF)

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications

Oncotarget, 2017-05, Vol.8 (20), p.33614-33620

2017

Volltextzugriff (PDF)

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A -Mutated Advanced Urothelial Carcinoma

Molecular cancer therapeutics, 2019-01, Vol.18 (1), p.185-195

2019

Volltextzugriff (PDF)

A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

BMC research notes, 2023-02, Vol.16 (1), p.16-16, Article 16

2023

Volltextzugriff (PDF)

Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas

Cancers, 2023-10, Vol.15 (21), p.5171

2023

Volltextzugriff (PDF)

Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis

Cancers, 2024-06, Vol.16 (11), p.2143

2024

Volltextzugriff (PDF)

Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance

Urologic oncology, 2024-07, Vol.42 (7), p.193-202

2024

Volltextzugriff (PDF)

Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma

Bladder cancer, 2021-01, Vol.7 (2), p.143-148

2021

Volltextzugriff (PDF)

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003388

2021

Volltextzugriff (PDF)

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e000705

2020

Volltextzugriff (PDF)

Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

JCO precision oncology, 2023-07, Vol.7, p.e2300095

2023

Volltextzugriff (PDF)

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

Journal for immunotherapy of cancer, 2023-10, Vol.11 (10), p.e007725

2023

Volltextzugriff (PDF)

A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers

Heliyon, 2022-09, Vol.8 (9), p.e10583-e10583, Article e10583

2022

Volltextzugriff (PDF)

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-01, Vol.11 (1), p.e005007

2023

Volltextzugriff (PDF)

Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool

Geriatrics (Basel), 2022-11, Vol.7 (6), p.133

2022

Volltextzugriff (PDF)

Identifying A Practical Measurement Of Physical Function To Implement Within An Outpatient Geriatric Oncology Clinic: 867

Medicine and science in sports and exercise, 2023-09, Vol.55 (9S), p.305-306

2023

Volltextzugriff (PDF)

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

The lancet oncology, 2021-07, Vol.22 (7), p.931-945

2021

Volltextzugriff (PDF)

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

The New England journal of medicine, 2021-11, Vol.385 (22), p.2036-2046

2021

Volltextzugriff (PDF)

Examination of real-world data from geriatric assessments in a comprehensive cancer center to explore predominant and cancer-specific domains for intervention

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e24027-e24027

2023

Volltextzugriff (PDF)

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Journal of clinical oncology, 2020-06, Vol.38 (16), p.1797-1806

2020

Volltextzugriff (PDF)

Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor

Translational andrology and urology, 2017-12, Vol.6 (6), p.1198-1202

2017

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA

Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study

Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial

Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A -Mutated Advanced Urothelial Carcinoma

A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas

Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis

Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance

Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery

Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool

Identifying A Practical Measurement Of Physical Function To Implement Within An Outpatient Geriatric Oncology Clinic: 867

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

Examination of real-world data from geriatric assessments in a comprehensive cancer center to explore predominant and cancer-specific domains for intervention

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor

Suchergebnisse filtern